{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:25:33Z","timestamp":1783059933320,"version":"3.54.6"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunohistochemistry (IHC) is widely used to determine estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status, which are crucial for predicting breast cancer recurrence and guiding adjuvant therapy decisions. While RNA expression levels, assessed by microarray, can also determine ER and HER2 status, they do not match IHC assessment results perfectly. This study investigated the discordance rates between IHC and RNA expression-based assessment of ER and HER2 status and evaluated the prognostic impact of such discrepancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>IHC\/FISH results for determining ER\/HER2 status were compared with RNA expression-based assessment. Recurrence-free survival (RFS) analysis was performed to evaluate the association between discordant results and clinical outcomes. Inverse Probability of Treatment Weighting (IPTW) was applied to adjust for potential confounding by differences in patient characteristics. Multivariate analysis was conducted to identify factors most strongly associated with ER\/HER2 discordance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The discordance rate was 11.8% for ER and 19.4% for HER2 when comparing IHC\/FISH with RNA expression-based assessment. Analysis of RFS suggested a possible association between discordant ER results and shorter RFS, although this did not reach statistical significance in unadjusted analysis. Using IPTW, discordance in both ER and HER2 status was found to be significantly related to worse RFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04, respectively). In multivariate analysis, PR-negative\/HER2-positive cases were most strongly associated with ER\/HER2 discordance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ER and HER2 RNA expression levels should be considered for confirmation in patients with PR-negative\/HER2-positive status, as discordance between IHC and RNA-based assessment is significantly associated with worse recurrence-free survival outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16081-4","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:34:58Z","timestamp":1778333698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Discordance between IHC\/FISH and RNA expression-based assessment of ER\/HER2 status, and its prognostic impact assessed by propensity score matching"],"prefix":"10.1186","volume":"26","author":[{"given":"Chiaki","family":"Nakauchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanae","family":"Masunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Tanei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"12","key":"16081_CR1","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38(12):1346\u201366. https:\/\/doi.org\/10.1200\/JCO.19.02309.","journal-title":"J Clin Oncol"},{"issue":"19","key":"16081_CR2","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1200\/JCO.2018.78.9620","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology-College of American Pathologists guideline update. J Clin Oncol. 2018;36(19):1996\u20132013. https:\/\/doi.org\/10.1200\/JCO.2018.78.9620.","journal-title":"J Clin Oncol"},{"issue":"22","key":"16081_CR3","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol. 2023;41(22):3867\u201372. https:\/\/doi.org\/10.1200\/JCO.22.02864.","journal-title":"J Clin Oncol"},{"issue":"6797","key":"16081_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352. https:\/\/doi.org\/10.1038\/35021093.","journal-title":"Nature"},{"issue":"8","key":"16081_CR5","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.18.1370.","journal-title":"J Clin Oncol"},{"issue":"21","key":"16081_CR6","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","volume":"16","author":"TO Nielsen","year":"2010","unstructured":"Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor\u2013positive breast cancer. Clin Cancer Res. 2010;16(21):5222\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1282.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"16081_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13058-017-0911-9","volume":"19","author":"HO Ohnstad","year":"2017","unstructured":"Ohnstad HO, Borgen E, Lien EA, et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res. 2017;19(1):120. https:\/\/doi.org\/10.1186\/s13058-017-0911-9.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"16081_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10549-019-05446-y","volume":"179","author":"M Pu","year":"2020","unstructured":"Pu M, Messer K, Davies SR, et al. Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Res Treat. 2020;179(1):197\u2013206. https:\/\/doi.org\/10.1007\/s10549-019-05446-y.","journal-title":"Breast Cancer Res Treat"},{"key":"16081_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-018-05120-9","volume":"174","author":"S Imanishi","year":"2019","unstructured":"Imanishi S, Naoi Y, Shimazu K, et al. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC. Breast Cancer Res Treat. 2019;174:627\u201337. https:\/\/doi.org\/10.1007\/s10549-018-05120-9.","journal-title":"Breast Cancer Res Treat"},{"key":"16081_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0076-6879(06)11019-8","volume":"411","author":"T Barrett","year":"2006","unstructured":"Barrett T, Edgar R. Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol. 2006;411:352\u201369. https:\/\/doi.org\/10.1016\/S0076-6879(06)11019-8.","journal-title":"Methods Enzymol"},{"issue":"5","key":"16081_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1349-7006.2012.02231.x","volume":"103","author":"T Miyake","year":"2012","unstructured":"Miyake T, Nakayama T, Naoi Y, et al. GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER\u2010negative breast cancer. Cancer Sci. 2012;103(5):913\u201320. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02231.x.","journal-title":"Cancer Sci"},{"issue":"27","key":"16081_CR12","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326. https:\/\/doi.org\/10.1056\/NEJMoa041588.","journal-title":"N Engl J Med"},{"issue":"23","key":"16081_CR13","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726\u201334. https:\/\/doi.org\/10.1200\/JCO.2005.04.7985.","journal-title":"J Clin Oncol"},{"issue":"2","key":"16081_CR14","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1804710.","journal-title":"N Engl J Med"},{"issue":"3","key":"16081_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-008-0242-8","volume":"118","author":"B Gyorffy","year":"2009","unstructured":"Gyorffy B, Schafer R. Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients. Breast Cancer Res Treat. 2009;118(3):433\u201341. https:\/\/doi.org\/10.1007\/s10549-008-0242-8. Epub 2008 Dec 5.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"16081_CR16","doi-asserted-by":"publisher","first-page":"e5645","DOI":"10.1371\/journal.pone.0005645","volume":"4","author":"B Gyorffy","year":"2009","unstructured":"Gyorffy B, Molnar B, Lage H, et al. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS ONE. 2009;4(5):e5645. https:\/\/doi.org\/10.1371\/journal.pone.0005645.","journal-title":"PLoS ONE"},{"issue":"3","key":"16081_CR17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gyorffy","year":"2010","unstructured":"Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725\u201331. https:\/\/doi.org\/10.1007\/s10549-009-0674-9. Epub 2009 Dec 18.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"16081_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/1471-2105-12-474","volume":"12","author":"Q Li","year":"2011","unstructured":"Li Q, Birkbak NJ, Gyorffy B, et al. Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics. 2011;12(1):474. https:\/\/doi.org\/10.1186\/1471-2105-12-474.","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"16081_CR19","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s10549-011-1676-y","volume":"132","author":"B Gyorffy","year":"2012","unstructured":"Gyorffy B, Benke Z, Lanczky A, et al. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat. 2012;132(3):1025\u201334. https:\/\/doi.org\/10.1007\/s10549-011-1676-y. Epub 2011 Jul 16.","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"16081_CR20","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/sim.5705","volume":"32","author":"PC Austin","year":"2013","unstructured":"Austin PC. The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med. 2013;32(16):2837\u201349. https:\/\/doi.org\/10.1002\/sim.5705.","journal-title":"Stat Med"},{"issue":"20","key":"16081_CR21","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1002\/sim.3854","volume":"29","author":"PC Austin","year":"2010","unstructured":"Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med. 2010;29(20):2137\u201348. https:\/\/doi.org\/10.1002\/sim.3854.","journal-title":"Stat Med"},{"issue":"4","key":"16081_CR22","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1177\/0962280215584401","volume":"26","author":"PC Austin","year":"2017","unstructured":"Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res. 2017;26(4):1654\u201370. https:\/\/doi.org\/10.1177\/0962280215584401.","journal-title":"Stat Methods Med Res"},{"issue":"17","key":"16081_CR23","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1002\/cncr.28710","volume":"120","author":"PA Kaufman","year":"2014","unstructured":"Kaufman PA, Bloom KJ, Burris H, et al. Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer. Cancer. 2014;120(17):2657\u201364. https:\/\/doi.org\/10.1002\/cncr.28710.","journal-title":"Cancer"},{"issue":"1","key":"16081_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-013-2444-y","volume":"138","author":"EA Perez","year":"2013","unstructured":"Perez EA, Press MF, Dueck AC, et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013;138(1):99\u2013108. https:\/\/doi.org\/10.1007\/s10549-013-2444-y.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"16081_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.4143\/crt.2018.342","volume":"51","author":"HK Kim","year":"2019","unstructured":"Kim HK, Park KH, Kim Y, et al. Discordance of the PAM50 intrinsic subtypes compared with immunohistochemistry-based surrogate in breast cancer patients: potential implication of genomic alterations of discordance. Cancer Res Treat. 2019;51(2):737\u201347. https:\/\/doi.org\/10.4143\/crt.2018.342. Epub 2018 Sep 5.","journal-title":"Cancer Res Treat"},{"issue":"3","key":"16081_CR26","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2325\/jbcs.13.232","volume":"13","author":"S Umemura","year":"2006","unstructured":"Umemura S, Kurosumi M, Moriya T, et al. Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol. Breast Cancer. 2006;13(3):232. https:\/\/doi.org\/10.2325\/jbcs.13.232.","journal-title":"Breast Cancer"},{"issue":"Suppl 2","key":"16081_CR27","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1038\/modpathol.2008.34","volume":"21","author":"AM Gown","year":"2008","unstructured":"Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(Suppl 2):S8\u201315. https:\/\/doi.org\/10.1038\/modpathol.2008.34.","journal-title":"Mod Pathol"},{"issue":"3","key":"16081_CR28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1210\/me.2004-0287","volume":"19","author":"BM Jacobsen","year":"2005","unstructured":"Jacobsen BM, Schittone SA, Richer JK, et al. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol. 2005;19(3):574\u201387. https:\/\/doi.org\/10.1210\/me.2004-0287.","journal-title":"Mol Endocrinol"},{"issue":"2","key":"16081_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/endrev\/bnz001","volume":"41","author":"B Trabert","year":"2020","unstructured":"Trabert B, Sherman ME, Kannan N, et al. Progesterone and breast cancer. Endocr Rev. 2020;41(2):320\u201344. https:\/\/doi.org\/10.1210\/endrev\/bnz001.","journal-title":"Endocr Rev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16081-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16081-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16081-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:12:26Z","timestamp":1783059146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16081-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16081"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16081-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. This study complied with the current laws of Japan. We ensured that all procedures involving human participants were approved by the Institutional Review Board of Osaka University Graduate School of Medicine and that informed consent was obtained from all participants prior to their enrollment in the study (approval number: 11337, date of approval: May 7, 2012).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"808"}}